Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.
A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.
Antonini
Giovanni
G
Department of Neurological Sciences, 2nd School of Medicine, University of Rome "La Sapienza", Rome, Italy.
Cox
Maria Cristina
MC
Montefusco
Enrico
E
Ferrari
Antonella
A
Conte
Esmeralda
E
Morino
Stefania
S
Latino
Pamela
P
Trasimeni
Guido
G
Monarca
Bruno
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000628:therapy*; D008577:Meningeal Neoplasms / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab